Here are the Form 4 insider transactions from Arbutus Biopharma Corporation (ABUS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ABUS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABUS filings page.
Robert A. Beardsley reported disposition transactions in this Form 4 filing. Arbutus Biopharma Corp (ABUS) director Robert A. Beardsley tendered 17,948 common shares to the issuer under its tender offer. The issuer took up and accepted the shares for payment on October 1, 2026, at $5 per share. Beardsley reported direct holdings of 14,328 common shares following the transaction.
Tuan Nguyen reported disposition transactions in this Form 4 filing. Arbutus Biopharma Corp (ABUS) took up and accepted for payment 48,081 common shares tendered by Chief Financial Officer Tuan Nguyen under its tender offer, at $5.00 per share. The company accepted the shares on October 1, 2026. Nguyen reported direct holdings of 111,882 common shares afterward; no Rule 10b5-1 plan is reported.
Roger Sawhney reported disposition transactions in this Form 4 filing. Arbutus Biopharma Corp (ABUS) director Roger Sawhney tendered 17,142 common shares from his direct holdings to the issuer under its tender offer at $5.0000 per share. The issuer took up and accepted the shares for payment on October 1, 2026. Sawhney held 13,683 common shares directly after the transaction.
Arbutus Biopharma Corp's President and CEO, Lindsay Androski, returned 24,655 common shares to the issuer in its tender offer at $5.00 per share on October 1, 2026. The issuer took up and accepted the shares for payment that day. Androski held 47,682 common shares directly following the transaction. No Rule 10b5-1 plan is reported.
Arbutus Biopharma Corp. reports that Roivant Sciences Ltd. returned 8,967,383 common shares to the issuer on October 1, 2026, at $5 per share. Roivant directly held 29,880,079 shares afterward. Roivant is a 10% owner and may be deemed a director by deputization; no Rule 10b5-1 plan is reported.
Arbutus Biopharma Corp (ABUS) President and CEO Lindsay Androski exercised stock options on September 18, 2026, acquiring 116,408 common shares at an exercise price of $3.20 per share and 10,456 common shares at $4.39 per share. The issuer withheld 82,527 shares, reported at $5.07 per share, to satisfy the aggregate exercise prices. No Rule 10b5-1 plan is reported.
Arbutus Biopharma Corp (ABUS) Chief Financial Officer Nguyen Tuan exercised options on September 18, 2026, for 265,625 common shares at an exercise price of $3.49 per share and 27,475 common shares at an exercise price of $4.39 per share. The issuer withheld 206,637 shares otherwise issuable upon the exercises to satisfy the aggregate exercise prices. The options represented rights to purchase 750,000 and 188,400 shares, respectively, and vest subject to continuous service.
On September 18, 2026, Arbutus Biopharma Corp director Roger Sawhney exercised options to acquire 52,533 common shares at $3.34 and 78,800 common shares at $4.24. The issuer withheld 100,508 shares otherwise issuable upon the exercises to satisfy the aggregate exercise prices. The 52,533-share exercise related to an option for 157,600 shares that vests in thirds on the first three anniversaries of August 4, 2025, subject to continuous service; the 78,800-share option was fully vested and exercisable as of its June 8, 2026 grant date.
Arbutus Biopharma Corp (ABUS) director Robert A. Beardsley exercised options for 52,533 shares at an exercise price of $3.20 and 78,800 shares at $4.24 on September 18, 2026. The first option covers 157,600 shares and vests over three years, subject to continuous service; the second option was fully vested and exercisable as of June 8, 2026. The issuer withheld 99,057 shares to satisfy the aggregate exercise prices. No Rule 10b5-1 plan is reported.
Arbutus Biopharma Corp director Roger Sawhney received a fully vested stock option grant covering 78,800 common shares. The option was granted at an exercise price of $4.24 per share, matching the closing price of the company’s common shares on Nasdaq on the grant date.
The option is immediately exercisable and expires on June 8, 2036. This transaction reflects an equity-based compensation award and does not involve any open-market purchase or sale of Arbutus Biopharma shares.
Arbutus Biopharma director Robert A. Beardsley was granted stock options to acquire 78,800 common shares. The options have an exercise price of $4.24 per share, are fully vested and exercisable as of the grant date, and expire on June 8, 2036. This is a compensation-related award, not an open-market purchase or sale.
Arbutus Biopharma Chief Financial Officer Tuan Nguyen reported new equity awards. On 02/02/2026, he received 73,500 restricted stock units (RSUs), each representing one common share, vesting in three equal annual installments starting one year after the grant, subject to continued service. Common shares will automatically be sold at each vesting date to cover tax withholding in a non‑discretionary way. He was also granted a stock option for 188,400 common shares at an exercise price of $4.39 per share, vesting over four years in substantially equal monthly installments beginning one month after the grant, also conditioned on continued service.
Arbutus Biopharma Corp
The RSUs vest in three equal annual installments beginning one year from the grant date, contingent on continued service, and shares will be automatically sold at vesting to cover tax withholding. She also received a stock option for 71,700 common shares at an exercise price equal to the Nasdaq closing price of $4.39 on the grant date.
This option vests over four years, with 1/48th of the shares vesting in substantially equal monthly installments starting one month after the grant date, subject to her continued service. After these grants, she directly holds 28,000 common shares and options for 71,700 shares.